{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:07:20Z","timestamp":1790222840576,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81302856"],"award-info":[{"award-number":["81302856"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.tube.2017.11.012","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T19:16:22Z","timestamp":1511550982000},"page":"28-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Rapid and sensitive method for simultaneous determination of first-line anti-tuberculosis drugs in human plasma by HPLC-MS\/MS: Application to therapeutic drug monitoring"],"prefix":"10.1016","volume":"109","author":[{"given":"Shouhong","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhai","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wansheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tube.2017.11.012_bib1","series-title":"Global tuberculosis report","author":"WHO","year":"2013"},{"issue":"9785","key":"10.1016\/j.tube.2017.11.012_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(10)62173-3","article-title":"Tuberculosis","volume":"378","author":"Lawn","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.tube.2017.11.012_bib3","first-page":"61","article-title":"The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis","volume":"79","author":"Blomberg","year":"2001","journal-title":"Bull World Health Organ"},{"issue":"7","key":"10.1016\/j.tube.2017.11.012_bib4","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.282.7.677","article-title":"Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO global surveillance and monitoring project","volume":"282","author":"Dye","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.tube.2017.11.012_bib5","unstructured":"Guidelines for diagnosis and treatment of pulmonary tuberculosis, China, version 2013."},{"key":"10.1016\/j.tube.2017.11.012_bib6","series-title":"Text book of adverse drug reaction","year":"1999"},{"issue":"2","key":"10.1016\/j.tube.2017.11.012_bib7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/14740338.5.2.231","article-title":"Adverse reactions to first-line antituberculosis drugs","volume":"5","author":"Forget","year":"2006","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"10.1016\/j.tube.2017.11.012_bib8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1517\/17425255.2014.895813","article-title":"Understanding pharmacokinetics to improve tuberculosis treatment outcome","volume":"10","author":"Reynolds","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"12","key":"10.1016\/j.tube.2017.11.012_bib9","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/infdis\/jir658","article-title":"Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability","volume":"204","author":"Srivastava","year":"2011","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.tube.2017.11.012_bib10","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1164\/rccm.200208-951OC","article-title":"Tuberculosis Trials Consortium. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine","volume":"167","author":"Weiner","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.tube.2017.11.012_bib11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12098-010-0304-x","article-title":"Pharmacokinetics of anti-tuberculosis drugs in children","volume":"78","author":"Ramachandran","year":"2011","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.tube.2017.11.012_bib12","article-title":"Pharmacokinetics of the first-line antituberculosis drugs in ghanaian children with tuberculosis with or without HIV coinfection","volume":"24","author":"Antwi","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.tube.2017.11.012_bib13","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/rcm.2961","article-title":"Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography\/tandem mass spectrometry","volume":"21","author":"Song","year":"2007","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"9","key":"10.1016\/j.tube.2017.11.012_bib14","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/jac\/dkt154","article-title":"Method for simultaneous analysis of nine second-line anti-tuberculosis drugs using UPLC-MS\/MS","volume":"68","author":"Han","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2017.11.012_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2012.12.023","article-title":"Troubleshooting carry-over of LC-MS\/MS method for rifampicin, clarithromycin and metabolites in human plasma","volume":"917\u2013918","author":"Vu","year":"2013","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"issue":"11","key":"10.1016\/j.tube.2017.11.012_bib16","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/apm.12590","article-title":"Simultaneous quantification of isoniazid, rifampicin, ethambutol and pyrazinamide by liquid chromatography\/tandem mass spectrometry","volume":"124","author":"Prahl","year":"2016","journal-title":"APMIS"},{"issue":"16\u201317","key":"10.1016\/j.tube.2017.11.012_bib17","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.jchromb.2009.04.023","article-title":"A rapid and robust liquid chromatography\/tandem mass spectrometry method for simultaneous analysis of anti-tuberculosis drugs\u2013ethambutol and pyrazinamide in human plasma","volume":"877","author":"Gong","year":"2009","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"10.1016\/j.tube.2017.11.012_bib18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jpba.2014.09.019","article-title":"Development and validation of liquid chromatography tandem mass spectrometry method for simultaneous quantification of first line tuberculosis drugs and metabolites in human plasma and its application in clinical study","volume":"102","author":"Hee","year":"2015","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.tube.2017.11.012_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpba.2014.08.026","article-title":"Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry","volume":"102","author":"Kim","year":"2015","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"10.1016\/j.tube.2017.11.012_bib20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.4155\/bio.12.11","article-title":"Analytical bias between species caused by matrix effects in quantitative analysis of a small-molecule pharmaceutical candidate in plasma","volume":"4","author":"Gray","year":"2012","journal-title":"Bioanalysis"},{"issue":"23","key":"10.1016\/j.tube.2017.11.012_bib21","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/BF01733779","article-title":"Pharmacokinetics of oral and intravenous rifampicin during chronic administration","volume":"63","author":"Loos","year":"1985","journal-title":"Klin Wochenschr"},{"issue":"1","key":"10.1016\/j.tube.2017.11.012_bib22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0163-7258(87)90052-0","article-title":"Influence of the enzyme induction by rifampicin on its presystemic metabolism","volume":"33","author":"Loos","year":"1987","journal-title":"Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.tube.2017.11.012_bib23","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00228-016-2083-4","article-title":"Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring","volume":"72","author":"Verbeeck","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.tube.2017.11.012_bib24","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1086\/507543","article-title":"Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes","volume":"43","author":"Nijland","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.tube.2017.11.012_bib25","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1378\/chest.126.6.1770","article-title":"Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients","volume":"126","author":"Li","year":"2004","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.tube.2017.11.012_bib26","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/cpt.164","article-title":"Antituberculosis drugs in children","volume":"98","author":"Schaaf","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.tube.2017.11.012_bib27","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1378\/chest.120.5.1520","article-title":"Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy","volume":"120","author":"Mehta","year":"2001","journal-title":"Chest"},{"issue":"5\u20136","key":"10.1016\/j.tube.2017.11.012_bib28","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1445-5994.2003.00390.x","article-title":"Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid","volume":"33","author":"Ray","year":"2003","journal-title":"Intern Med J"},{"issue":"10","key":"10.1016\/j.tube.2017.11.012_bib29","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.3201\/eid1610.100374","article-title":"Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA","volume":"16","author":"Heysell","year":"2010","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"10.1016\/j.tube.2017.11.012_bib30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1155\/2011\/307150","article-title":"Therapeutic drug monitoring in the treatment of active tuberculosis","volume":"18","author":"Babalik","year":"2011","journal-title":"Can Respir J"},{"issue":"1","key":"10.1016\/j.tube.2017.11.012_bib31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pupt.2011.12.001","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis patients","volume":"25","author":"Magis-Escurra","year":"2012","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.tube.2017.11.012_bib32","first-page":"129723","article-title":"Early therapeutic drug monitoring for isoniazid and rifampin among diabetics with newly diagnosed tuberculosis in Virginia, USA","volume":"2013","author":"Heysell","year":"2013","journal-title":"Tuberc Res Treat"},{"issue":"2","key":"10.1016\/j.tube.2017.11.012_bib33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5588\/ijtld.12.0279","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis","volume":"17","author":"Van Tongeren","year":"2013","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979217301233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979217301233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T08:39:32Z","timestamp":1565339972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979217301233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":33,"alternative-id":["S1472979217301233"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2017.11.012","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid and sensitive method for simultaneous determination of first-line anti-tuberculosis drugs in human plasma by HPLC-MS\/MS: Application to therapeutic drug monitoring","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2017.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}